非小细胞肺癌中EGFR外显子20插入变异的分布与可检测性
本研究在临床试验(NCT02716116)、德国病历回顾研究及LC-SCRUM-Japan、GENIE、美国COTA数据库中回顾性分析636例携带EGFR外显子20插入(ex20ins)变异的NSCLC患者,共识别104种独特变异;各数据集中仅靠任一PCR检测可检出者的比例为11.8%至58.9%,提示所评估的PCR检测会漏检超过40%的患者,基于NGS的基因检测更可取。
要点
- 各数据集中仅用任一PCR检测可检出ex20ins的患者比例为11.8%至58.9%。
- 共636例患者纳入分析,跨数据源识别出104种独特EGFR ex20ins变异。
- 作者认为所评估的PCR检测会漏检超过40%的EGFR ex20ins患者,NGS检测更可取。
核心结论
- 作者认为所评估的PCR检测会漏检超过40%的携带EGFR ex20ins变异的NSCLC患者,基于NGS的基因检测优于标准PCR检测,可大幅提高对多样ex20ins变异的识别。
研究设计与样本
- 回顾性分析,纳入接受NGS或其他测序检测且已知携带EGFR ex20ins变异的NSCLC患者,来源于临床试验NCT02716116、德国病历回顾研究及LC-SCRUM-Japan、GENIE、美国COTA数据库。
- 共纳入636例携带EGFR ex20ins变异的NSCLC患者,跨数据源识别出104种独特变异。
- 在各数据集中计算可被六种市售且广泛使用的PCR试剂盒检出的ex20ins变异患者比例。
主要发现
- 共636例NSCLC患者纳入分析,跨数据源共识别104种独特EGFR ex20ins变异。
- 仅用任一PCR检测可检出ex20ins的患者比例在各数据源中为11.8%至58.9%。
关键数值与推荐
- 仅用任一PCR检测可检出ex20ins的患者比例范围为11.8%至58.9%(各数据源不同)。
- 共识别104种独特EGFR ex20ins变异,纳入636例患者。
临床怎么用
- 作者认为基于NGS的基因检测优于标准PCR检测,可大幅提高对NSCLC中多样EGFR ex20ins变异的识别。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: EGFR exon 20 insertion (ex20ins) mutations represent 5% to 10% of EGFR mutations in NSCLC. Identifying patients with EGFR ex20ins is challenging owing to the limited coverage of polymerase chain reaction (PCR) assays and the relatively recent use of next-generation sequencing (NGS). This study analyzes the spectrum of EGFR ex20ins variants in a large patient population from a global clinical trial and several real-world cohorts and the ability of PCR kits to identify these alterations. METHODS: We conducted this retrospective analysis in patients with NSCLC who underwent NGS or other sequencing testing and had a known EGFR ex20ins mutation. Patients were gathered from a clinical trial (NCT02716116), a chart review study in Germany, and the LC-SCRUM-Japan, GENIE, and U.S. COTA databases. Proportions of patients with ex20ins variants that could have been detected by six commercially available and widely used PCR kits were calculated in each data set. RESULTS: Overall, 636 patients with NSCLC harboring EGFR ex20ins mutations were included in this analysis and 104 unique EGFR ex20ins variants were identified across the data sources. The proportion of patients whose ex20ins could have been detected by any PCR test alone ranged from 11.8% to 58.9% across the data sources. CONCLUSIONS: Our findings suggest that the PCR tests evaluated would have missed more than 40% of patients with NSCLC harboring EGFR ex20ins mutations. NGS-based genetic testing is preferable than standard PCR assays and can substantially improve the identification of the diverse profile of EGFR ex20ins variants in NSCLC.
引用
- Ou SI, Hong JL, Christopoulos P, et al. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC. J Thorac Oncol. 2023. PMID: 36738930. doi:10.1016/j.jtho.2023.01.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。